All Articles
A Guide to accelerating the development and commercialization of Precision Medicine Diagnostics
View Report
Companion Diagnostics 101

Companion Diagnostics 101

10 February, 2021

Featured

Articles

Voices of stakeholders powerful in achieving success as CMS rescinds retirement of diagnosis codes

Read more

The Companion Diagnostics 101 Report is an industry expert's introduction for professionals working in the development and commercialization of Precision Medicine diagnostics.

View the report to get a comprehensive insight into the role of Companion Diagnostics in Precision Medicine and understand some of the key concepts, principles and terminology essential to the rollout of a successful commercial therapy launch.

What you will learn:

  • What is Precision Medicine?
  • What is a Biomarker?
  • What is a Companion Diagnostic (CDx)?
  • What Form Can a CDx Take?
  • Development of Precision Medicines and Companion Diagnostics Happens Simultaneously
  • The Six Barriers to Testing Adoption
  • How to Increase the Chances of Sufficient Reimbursement for Your CDx Test
  • Glossary of Precision Medicine Terms



About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane
London
EC4V 5EQ.

Tel: +44 (0)20 3405 0205 or [email protected]


 
Caroline Forde
Robyn Fisher
 
Kieran Breheny